Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.63% |
Capricor Therapeutics, Inc. NASDAQ:CAPR | $551.90M | $9.53 | Not rated | -13.9 | +42.38% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -19.72% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -4.87% |
Kyverna Therapeutics, Inc. NASDAQ:KYTX | $312.31M | $5.05 | Not rated | -3.1 | -42.78% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | $11.02 | Not rated | -8.3 | -30.51% |
Vanda Pharmaceuticals Inc. NASDAQ:VNDA | $241.27M | $3.99 | Not rated | -1.4 | -29.91% |
Amarin Corporation plc NASDAQ:AMRN | $235.37M | $11.38 | Not rated | -9.9 | -32.62% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -60.98% |
Mereo BioPharma Group plc NASDAQ:MREO | $49.10M | $0.31 | Not rated | -1.4 | -82.42% |
Continue the stock analysis
Jump to another research area for this company.